fecal sample of gastric pre-cancer before eradicating H. pylori
(12) 國立成功大學醫學系內科學科 - 鄭修琦醫師團隊
fecal , pre-cancer , Helicobacter pylori
Datasets
24 results
Gastric microbes associated with regression or progression of precancerous conditions after H. pylori eradication
(12) 國立成功大學醫學系內科學科 - 鄭修琦醫師團隊
Successful eradication of H. pylori halted the progression of gastric precancerous conditions; however, it did not guarantee that gastric cancer would not develop. Persistent gastric inflammation is one of the factors to predict disease progress...
探討「手術」、「運動」、「營養」透過腸-肝軸線改善脂肪肝炎與逆轉肝纖維化之機制並發展新穎 微生物治療策略
(04) 國立臺灣大學醫學院內科 - 吳明賢醫師團隊
1. 比較人的術前術後還有non-NASH跟NASH 2. 比較DONOR跟RECIPIENT的差異, NON-NASH跟NASH以及飲食的差異 3. 比較DONOR跟RECIPIENT的差異, 術前術後以及飲食的差異
Lean-Associated Microbiome Project in Taiwan (LAMP-Taiwan)
(07) 財團法人國家衛生研究院免疫醫學研究中心 - 高承源教授團隊
The human gut microbiome of baseline and lean subject groups is profiled with 16S rRNA gene based next generation sequencing.
The humanized gut microbiome of obesity-resistant mice in diet-induced obesity
(07) 財團法人國家衛生研究院免疫醫學研究中心 - 高承源教授團隊
The gut microbiome of obesity-resistant dusp6 knockout and wild-type control mice before or after ABX/FMT treatment (humanized gut microbiome) in diet-induced obesity is profiled with 16S rRNA gene based next generation sequencing.
Fecal microbiota compostion from CTL or CS mice treated by either ABX, NEO, AMP or VAN
(06) 長庚大學醫學生物技術暨檢驗學系 - 賴信志教授團隊
mice, 16S V3/V4
Fecal microbial composition of CS-recipient mice treated by fecal microbiota from CTL or CS mice treated by either ABX, NEO, AMP or VAN
(06) 長庚大學醫學生物技術暨檢驗學系 - 賴信志教授團隊
Mice, 16S rRNA, V3/V4
CJLDemo01 Mouse gut metagenome of HFD mice after receiving Ganoderma lucidum treated fecal transplant
HMP教學群組
Demo to exmine whether the anti-obesity effect of Ganoderma lucidum is transmissible via fecal transplanation